Escherichia coli Nissle 1917 (EcN)
Also called: E. coli Nissle 1917, EcN, E. coli strain Nissle 1917, E. coli DSM 6601
Escherichia coli Nissle 1917 (EcN; DSM 6601) is a probiotic E. coli strain used since about 1917 as the active ingredient of a licensed medicinal product in Germany and other countries. Its genome carries the pks island for the genotoxin colibactin.
- Category
- Probiotic
- Forms
- Live bacteria, studied as an oral preparation (adults), an oral suspension (young children) and rectal enemas; amounts stated as viable cells
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 2 Moderately studied in people. No review we found states a count of RCTs of EcN alone (a 2015 meta-analysis pooled 6 trials without stating randomization). We confirmed 10 randomized trials: ulcerative colitis (1997, 1999, 2004; 2010, rectal enemas; 2014), childhood diarrhea (2007, 2008), IBS (2012, 2015) and recurrent urinary infection (2026). [8]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BPregnancy and infants2 topics
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Ulcerative colitis: relapse and remission versus mesalazine (pooled trials) | B | A 2015 meta-analysis of 6 trials (719 patients) found relapse rates similar with EcN and mesalazine (36.8% vs 36.1%); remission induction was similar to controls, and only one study used a placebo comparison. [6] |
| Active ulcerative colitis, EcN added to conventional therapy | X | In a double-blind RCT of 100 patients, EcN add-on without prior ciprofloxacin gave fewer remissions than placebo (54% vs 89%, per protocol) and the most withdrawals. [10] |
| Acute diarrhea in infants and toddlers | B | In a double-blind RCT of 113 children aged 2–47 months, EcN suspension shortened the median time to treatment response (2.5 vs 4.8 days) versus placebo. [8] |
| Diarrhea lasting more than 4 days in infants and toddlers | B | In an RCT of 151 children aged 1–47 months, 21 days of EcN raised response rates versus placebo (day 21: 98.7% vs 71.1%). [9] |
| Irritable bowel syndrome | C | A 2026 meta-analysis of 2 placebo-controlled RCTs of EcN alone found no significant difference from placebo in reduction of abdominal pain or urgency. [16] |
Main constituents: E. coli strain Nissle (serotype O6:K5:H1) [5]; pks pathogenicity island coding for biosynthesis of the genotoxin colibactin, a DNA alkylator [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Ulcerative colitis maintenance RCT (327 patients): the EcN preparation 200 mg once daily for 12 months (comparator: mesalazine 500 mg three times daily). [7]
- Children aged 2–47 months: 1–3 mL/day of oral suspension containing 10^8 viable EcN cells per mL, depending on age. [8]
- Rectal use: 10, 20 or 40 mL enemas containing 10^8 EcN/mL once daily for at least 2 weeks; the ITT (all randomized patients) responder rate was not significantly higher than placebo. [11]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked. The profile notes other test results.
Details and sources - FDA new dietary ingredient notifications1 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- EcN produced colibactin and caused DNA cross-links and gene mutations in exposed epithelial cells, and DNA damage in mouse models of gut colonization; the authors call this a serious safety concern for risk-benefit evaluation. [2]
- Standard and adapted Ames tests and an in vivo comet assay in rats (10^9–10^11 CFU) found no detectable genotoxicity; most authors were employed by the producer of EcN products. [3]
- A 2024 review concludes that conflicting findings on EcN genotoxicity need further research to clarify its safety. [4]
- In the 2015 ulcerative colitis meta-analysis, side effects were comparable with EcN and mesalazine (OR 1.44, 95% CI 0.80–2.59). [6]
- FDA (2023, probiotics in general): administering probiotics to preterm infants may cause infection or invasive and potentially fatal disease; FDA reported one infant death and more than two dozen other adverse events. [17]
- ODS (probiotics in general): probiotics may cause harm in certain populations, including people who are severely ill or immunocompromised. [17]
Identity, quality and standardization
Regulatory status
- Germany and other countries: for nearly 100 years EcN has been the active pharmaceutical ingredient in a licensed medicinal product. [1]
- Canada: Escherichia coli is listed in Appendix I (Table 6) of Health Canada's probiotics monograph (April 24, 2026) as excluded from the monograph and its compendial application process. [18]
- US: FDA's published NDI notification list has 1 entry naming Escherichia coli strain Nissle 1917 (NDI 733 submitted 2011-08-15). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [19]
- US: No GRAS notice naming E. coli Nissle 1917 was found in FDA's GRAS Notice Inventory (checked 2026-10-30). [20]
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [21]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 1 entry naming Escherichia coli strain Nissle 1917 (NDI 733 submitted 2011-08-15). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P3]
- No GRAS notice naming E. coli Nissle 1917 was found in FDA's GRAS Notice Inventory (checked 2026-10-30). [P4]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of Escherichia coli Nissle 1917 was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-30). [P6]
- Genotoxicity research (not a carcinogenicity classification): EcN produced colibactin and induced mutagenic DNA damage in cultured cells and DNA damage in mouse gut; colibactin is linked to mutations found in human colorectal cancer. [P2]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P8]
- Genome screen for the pks (colibactin) island and other virulence-associated elements — EcN carries the pks island; reviewers urge thorough profiling of probiotics for harmful genetic elements. [P5]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Kruis W, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11(5):853-8 (PMID 9354192), 1997-10. pubmed.ncbi.nlm.nih.gov
- Nougayrède JP, et al. A toxic friend: genotoxic and mutagenic activity of the probiotic strain Escherichia coli Nissle 1917. mSphere 2021;6(4):e0062421 (PMID 34378987), 2021-08-25. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory (searchable list, checked 2026-10-30), 2026-10-30. hfpappexternal.fda.gov
- Falzone L, et al. Benefits and concerns of probiotics: an overview of the potential genotoxicity of the colibactin-producing Escherichia coli Nissle 1917 strain. Gut Microbes 2024;16(1):2397874 (PMID 39229962), 2024-09-04. pubmed.ncbi.nlm.nih.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- Sonnenborn U. Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiol Lett 2016;363(19):fnw212 (PMID 27619890), 2016-10. pubmed.ncbi.nlm.nih.gov
- Nougayrède JP, et al. A toxic friend: genotoxic and mutagenic activity of the probiotic strain Escherichia coli Nissle 1917. mSphere 2021;6(4):e0062421 (PMID 34378987), 2021-08-25. pubmed.ncbi.nlm.nih.gov
- Dubbert S, et al. No genotoxicity is detectable for Escherichia coli strain Nissle 1917 by standard in vitro and in vivo tests. Eur J Microbiol Immunol (Bp) 2020;10(1):11-19 (PMID 32363034), 2020-03-17. pubmed.ncbi.nlm.nih.gov
- Falzone L, et al. Benefits and concerns of probiotics: an overview of the potential genotoxicity of the colibactin-producing Escherichia coli Nissle 1917 strain. Gut Microbes 2024;16(1):2397874 (PMID 39229962), 2024-09-04. pubmed.ncbi.nlm.nih.gov
- Kruis W, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11(5):853-8 (PMID 9354192), 1997-10. pubmed.ncbi.nlm.nih.gov
- Losurdo G, et al. Escherichia coli Nissle 1917 in ulcerative colitis treatment: systematic review and meta-analysis. J Gastrointestin Liver Dis 2015;24(4):499-505 (PMID 26697577), 2015-12. pubmed.ncbi.nlm.nih.gov
- Kruis W, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53(11):1617-23 (PMID 15479682), 2004-11. pubmed.ncbi.nlm.nih.gov
- Henker J, et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 2007;166(4):311-8 (PMID 17287932), 2007-04. pubmed.ncbi.nlm.nih.gov
- Henker J, et al. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J 2008;27(6):494-9 (PMID 18469732), 2008-06. pubmed.ncbi.nlm.nih.gov
- Petersen AM, et al. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis 2014;8(11):1498-505 (PMID 24972748), 2014-11. pubmed.ncbi.nlm.nih.gov
- Matthes H, et al. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010;10:13 (PMID 20398311), 2010-04-15. pubmed.ncbi.nlm.nih.gov
- Rembacken BJ, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354(9179):635-9 (PMID 10466665), 1999-08-21. pubmed.ncbi.nlm.nih.gov
- Kruis W, et al. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012;27(4):467-74 (PMID 22130826), 2012-04. pubmed.ncbi.nlm.nih.gov
- Faghihi AH, et al. Efficacy of probiotic Escherichia coli Nissle 1917 in patients with irritable bowel syndrome: a double blind placebo-controlled randomized trial. Acta Med Indones 2015;47(3):201-8 (PMID 26586385), 2015-07. pubmed.ncbi.nlm.nih.gov
- Cerruto MA, et al. Escherichia coli Nissle 1917 for the prevention of recurrent uncomplicated urinary tract infections in women: a pilot randomized placebo-controlled trial. Arch Ital Urol Androl 2026;98(3):15699 (PMID 42803671), 2026-09-25. pubmed.ncbi.nlm.nih.gov
- Maslennikov R, et al. Strain-specific systematic review with meta-analysis of probiotics efficacy in the treatment of irritable bowel syndrome. J Clin Med 2026;15(3):1152 (PMID 41682832; full text PMC12898053), 2026-02-02. pmc.ncbi.nlm.nih.gov
- NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals (Updated March 25, 2025), 2025-03-25. ods.od.nih.gov
- Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory (searchable list, checked 2026-10-30), 2026-10-30. hfpappexternal.fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in probiotic: Akkermansia muciniphila (pasteurized) · Bacillus coagulans (Heyndrickxia coagulans) · Bifidobacterium animalis subsp. lactis BB-12 · Lacticaseibacillus paracasei strain Shirota (LcS) · Lacticaseibacillus rhamnosus GG (LGG) · Lactiplantibacillus plantarum 299v · Limosilactobacillus reuteri DSM 17938 · Probiotics · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.